Haematology

CAR-T in multiple myeloma
#CAR-T #Caribou Biosciences #Cell therapy #Haematology #Oncology

Caribou Biosciences cancels allogeneic CAR-T programmes

Caribou Biosciences has announced that it is discontinuing its two allogeneic CAR-T cell therapy programmes due to financing constraints.  It will discontinue development of vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. … Read More

#Cancer Research #News

#Haematology #Ipsen #Mergers and acquisitions #Oncology

Ipsen acquires Kartos Therapeutics in $450m deal 

Biopharmaceutical company Ipsen has agreed a deal to acquire Kartos Therapeutics, expanding its haemato-oncology late-stage pipeline.  Ipsen will pay $450 million upfront as per the terms of the agreement, with Kartos Therapeutics shareholders eligible to receive payments of up to $1.3 million subject to regulatory approval milestones and sales-based milestones.  The merger allows Ipsen to… Read More

#Business & Investment #News

#ASGCT #Cell and gene therapy #Clinical trial #Haematology

Therapy for X-CGD shows early promise, Ensoma reports 

An in vivo therapy being developed to treat X-linked chronic granulomatous disease (X-CGD) has shown positive early results.  EN-374, developed by cellular engineering company Ensoma, has demonstrated tolerability in the first participant being evaluated in the Phase I/II trial.  The therapy is a first-in-class in vivo haematopoietic stem cell… Read More

#News

#Bacteria #Blood cancer #Cancer Research UK #HaemaLogiX #Haematology #Institute of Cancer Research #Myeloma #Neuroscience #NHS #Oncology #Orphan drugs #Parkinson's #Rare diseases #University of Edinburgh

This week in Drug Discovery (16 – 20 March) 

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.  This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.  The top stories:    Edinburgh team… Read More

#News

Multiple myeloma
#Cancer drug targets #HaemaLogiX #Haematology #Myeloma #Oncology

Research identifies new targets for multiple myeloma treatment

New research published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma.  These antigens are present on malignant plasma cells but… Read More

#Cancer Research #News

FDA headquarters
#FDA #Haematology #Oncology #Pentixapharm #Radiopharmaceuticals

FDA approves Pentixapharm’s dual theranostic INDs

The US Food and Drug Administration (FDA) has approved a clinical study of Pentixapharm’s CXCR4-targeted theranostic programme in haemato-oncology, following a 30-day safety review of two Investigational New Drug (IND) applications.  The two IND submissions support the single PENTHERA Phase I/II protocol, which evaluates the combined use of PentixaFor imaging… Read More

#News #Regulatory

Leukaemia
#Amgen #Haematology #Mergers and acquisitions #Oncology

Amgen acquires Dark Blue Therapeutics for $840 million

Oncology biotech Dark Blue Therapeutics has been acquired by Amgen for up to $840 million, including upfront and future milestones.  Dark Blue's lead candidate DBT 3757, currently in IND-enabling studies, represents a first-in-class therapeutic strategy for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), with the potential for producing… Read More

#Business & Investment #News

Blood cells
#ASH 2025 #CAR-T #Events #Haematology #Oncology

ASH 2025: New clinical findings in haematology

The 67th American Society of Hematology (ASH) Annual Meeting and Exposition took place 6-9 December 2025, in Orlando, Florida. Diana Turner rounds up the latest clinical trial data shared at the meeting.  Early-stage trials KLN-1010 for multiple myeloma Kelonia Therapeutics announced the first results from the ongoing inMMyCAR study, a… Read More

#Exclusive Content

CAR-T for large B-cell lymphoma
#Advanced Therapies #Bristol Myers Squibb #FDA #Haematology #Lymphoma #Oncology

FDA approves first CAR-T therapy for marginal zone lymphoma

The US Food and Drug Administration (FDA) has approved a new indication for Breyanzi (lisocabtagene maraleucel) as the first chimeric antigen receptor (CAR)-T therapy in the US for treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of… Read More

#News #Regulatory

Haematology
#Biotech #Financing #Haematology #Immunology

Star Therapeutics announces $125 million financing for VWD therapy

Biotechnology company Star Therapeutics has announced its $125 million Series D financing round was oversubscribed and will now initiate a clinical trial of its von Willebrand disease (VWD) therapy.  The financing round was co-led by Sanofi Ventures and Viking Global Investors, with participation from both… Read More

#News

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #Haematology #In vivo #Lipid based nanoparticle (LNP) #NanoCell Therapeutics #Oncology

First non-viral DNA-based in vivo CAR-T generation

A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery.  The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More

#Cancer Research #News #Trending News

Monoclonal antibodies
#FDA #Haematology #Myeloma #Oncology #Orphan drugs #Sanofi

Sanofi’s antibody earns orphan status for multiple myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb).  The mAb targets G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM).  … Read More

#Cancer Research #News #Regulatory

Scientist conducts tests in the lab
#AstraZeneca #Haematology #Monoclonal antibodies #Phase III trial

AZ’s anselamimab fails to meet primary endpoint in amyloidosis trial

High-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical programme show that anselamimab did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis.   The primary endpoint was defined… Read More

#News

Leukaemia
#Ascentage Pharma #Blood cancer #China #Haematology #Oncology

First Bcl-2 inhibitor approved in China for CLL/SLL

Ascentage Pharma’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).  It is approved in patients who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. … Read More

#News #Regulatory

Molecular,Model,Of,Antibody
#Antibody #Clinical trials #Haematology #Harvard Medical School #ITP #Monoclonal antibodies #Platelet biology #Takeda

Mezagitamab and the future of ITP treatment

The International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress took place in Washington DC from 21-25 June 2025. At this event, Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody (mAb), in patients with persistent or chronic primary immune thrombocytopenia… Read More

#Exclusive Content

Blood cells
#CSL Behring #Early access #Gene therapy #Haematology #Haemophilia

First patient receives gene therapy for haemophilia B in Germany

CSL Behring Germany has announced that the first haemophilia B patient in Germany was treated with the gene therapy Hemgenix (etranacogene dezaparvovec) at the Hemophilia Treatment Center at Hannover Medical School. Hemgenix is the first one-time gene therapy approved in Europe for the treatment of adults with severe… Read More

#News